These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 19279350)

  • 1. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Koretz RL; Gluud C
    N Engl J Med; 2009 Mar; 360(11):1151; author reply 1152-3. PubMed ID: 19279350
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Poynard T; Ratziu V
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283890
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Hoshida Y; Golub TR
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283891
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of compensated liver cirrhosis with hepatitis C virus of genotype 1b and high viral load in whom sustained virological response was achieved by 2-year administration of very low-dose recombinant interferon alpha-2b.
    Kato H; Nakamura M; Nakamura A; Ueda R
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):121-2. PubMed ID: 19959940
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effectiveness of long-acting interferon (peginterferon)].
    Kondo Y; Tateishi R; Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):515-8. PubMed ID: 15359853
    [No Abstract]   [Full Text] [Related]  

  • 6. [Peginterferon alpha and ribavirin therapy for difficult-to-treat chronic hepatitis C patients].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2002; 56 Suppl 4():51-4. PubMed ID: 14750261
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term combined therapy with very-low-dose peginterferon and ursodeoxycholic acid decreased the spleen size in a patient with hepatitis C virus-related cirrhosis.
    Anzai T; Miyake Y; Yasuhara H; Miyatake H; Asagi A; Moriya A; Nakatsu M; Ando M; Hirohata M
    Intern Med; 2013; 52(3):363-7. PubMed ID: 23370746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two-step interferon rebound therapy].
    Kato M; Yuki N; Iyoda K; Yamamoto K; Hayashi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):497-501. PubMed ID: 15359849
    [No Abstract]   [Full Text] [Related]  

  • 10. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic hepatitis C viral infection with persistent normal serum alanine aminotransferases].
    Huang CX; Bai XF
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):70-1. PubMed ID: 15670508
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of patients with chronic hepatitis C who never had been treated].
    Hézode C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B38-49. PubMed ID: 12180307
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 14. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Puoti C; Bellis L; Castellacci R; Montagnese F
    Hepatology; 2005 Mar; 41(3):683; author reply 684. PubMed ID: 15723301
    [No Abstract]   [Full Text] [Related]  

  • 15. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
    Wirth S; Pieper-Boustani H; Lang T; Ballauff A; Kullmer U; Gerner P; Wintermeyer P; Jenke A
    Hepatology; 2005 May; 41(5):1013-8. PubMed ID: 15793840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F; Al-Khaldi J; Asker H; Al-Ajmi M; Owayed S; Varghese R; Siddique I; Al-Nakib B
    Antivir Ther; 2004 Aug; 9(4):499-503. PubMed ID: 15456080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus.
    Cholongitas E; Samonakis D; Patch D; Senzolo M; Burroughs AK; Quaglia A; Dhillon A
    Transplantation; 2006 Feb; 81(3):488-90. PubMed ID: 16477242
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
    Cuccorese G; Tursi A; Spinazzola AM; Modeo ME; Miglietta A
    Am J Gastroenterol; 2000 Sep; 95(9):2399-400. PubMed ID: 11007262
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
    Patel MR; Mullen MP; Dieterich DT
    AIDS Read; 2006 Mar; 16(3):164, 168-9; discussion 168-9. PubMed ID: 16538956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.